185 related articles for article (PubMed ID: 36585123)
1. [Not Available].
Karras A
Nephrol Ther; 2022 Dec; 18(6S1):6S7-6S10. PubMed ID: 36585123
[TBL] [Abstract][Full Text] [Related]
2. Avacopan in the treatment of ANCA-associated vasculitis.
Tesar V; Hruskova Z
Expert Opin Investig Drugs; 2018 May; 27(5):491-496. PubMed ID: 29718732
[TBL] [Abstract][Full Text] [Related]
3. Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.
Jayne DRW; Bruchfeld AN; Harper L; Schaier M; Venning MC; Hamilton P; Burst V; Grundmann F; Jadoul M; Szombati I; Tesař V; Segelmark M; Potarca A; Schall TJ; Bekker P;
J Am Soc Nephrol; 2017 Sep; 28(9):2756-2767. PubMed ID: 28400446
[TBL] [Abstract][Full Text] [Related]
4. Avacopan for the Treatment of ANCA-Associated Vasculitis.
Jayne DRW; Merkel PA; Schall TJ; Bekker P;
N Engl J Med; 2021 Feb; 384(7):599-609. PubMed ID: 33596356
[TBL] [Abstract][Full Text] [Related]
5. Avacopan: First Approval.
Lee A
Drugs; 2022 Jan; 82(1):79-85. PubMed ID: 34826105
[TBL] [Abstract][Full Text] [Related]
6. Avacopan as an additional therapeutic intervention to promote renal recovery in severe ANCA-associated vasculitis: A case report.
Atrens AD; Hutton H; O'Sullivan E; Moore J; Madhan K
Nephrology (Carlton); 2024 Feb; 29(2):105-107. PubMed ID: 37985226
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial.
Geetha D; Dua A; Yue H; Springer J; Salvarani C; Jayne D; Merkel P;
Ann Rheum Dis; 2024 Jan; 83(2):223-232. PubMed ID: 37979959
[TBL] [Abstract][Full Text] [Related]
8. Use of avacopan in severe forms of ANCA-associated vasculitis. Comment on "Inhibiting C5a/C5aR to treat ANCA-associated vasculitides" by Terrier et al. Joint Bone Spine 2023;90:105472.
Astouati Q; Provot F; Farhat MM; Launay D; Sanges S
Joint Bone Spine; 2023 Mar; 90(2):105522. PubMed ID: 36623800
[No Abstract] [Full Text] [Related]
9. Complement inhibition in ANCA vasculitis.
Jayne D
Nephrol Ther; 2019 Nov; 15(6):409-412. PubMed ID: 31631015
[TBL] [Abstract][Full Text] [Related]
10. Avacopan for the treatment of ANCA-associated vasculitis.
Osman M; Cohen Tervaert JW; Pagnoux C
Expert Rev Clin Immunol; 2021 Jul; 17(7):717-726. PubMed ID: 34006155
[No Abstract] [Full Text] [Related]
11. Avacopan for the treatment of ANCA-associated vasculitis: an update.
Osman M; Cohen Tervaert JW; Pagnoux C
Expert Rev Clin Immunol; 2023 May; 19(5):461-471. PubMed ID: 36545762
[TBL] [Abstract][Full Text] [Related]
12. How the Availability of Anti-C5a Agents Could Change the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Roccatello D; Fenoglio R; Oddone V; Sciascia S
Kidney Blood Press Res; 2022; 47(8):506-513. PubMed ID: 35665698
[TBL] [Abstract][Full Text] [Related]
13. Avacopan, a selective C5a receptor antagonist, for anti-neutrophil cytoplasmic antibody-associated vasculitis.
Harigai M; Takada H
Mod Rheumatol; 2022 Apr; 32(3):475-483. PubMed ID: 34984461
[TBL] [Abstract][Full Text] [Related]
14. AVACOPAN: A New Adjunctive Therapy for Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Garg J; Frishman WH
Cardiol Rev; 2023 Jan-Feb 01; 31(1):3-6. PubMed ID: 36469359
[TBL] [Abstract][Full Text] [Related]
15. Complement Inhibition in ANCA-Associated Vasculitis.
Tesar V; Hruskova Z
Front Immunol; 2022; 13():888816. PubMed ID: 35880179
[TBL] [Abstract][Full Text] [Related]
16. The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial.
Strand V; Jayne DRW; Horomanski A; Yue H; Bekker P; Merkel PA;
Lancet Rheumatol; 2023 Aug; 5(8):e451-e460. PubMed ID: 38251577
[TBL] [Abstract][Full Text] [Related]
17. Avacopan, a Novel Competitive C5a Receptor Antagonist, for Severe Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis.
Nguyen ID; Sinnathamby ES; Mason J; Urban B; Neuchat EE; Wenger DM; Ahmadzadeh S; Shekoohi S; Kaye AD
Clin Drug Investig; 2023 Aug; 43(8):595-603. PubMed ID: 37596445
[TBL] [Abstract][Full Text] [Related]
18. A projected cost-utility analysis of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis in Spain.
Macía M; Díaz-Encarnación M; Solans-Laqué R; Mallol EP; Castells AG; Escribano C; de Arellano AR
Expert Rev Pharmacoecon Outcomes Res; 2024 Feb; 24(2):227-235. PubMed ID: 38126738
[TBL] [Abstract][Full Text] [Related]
19. Glucocorticoid Toxicity Index scores by domain in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with avacopan versus standard prednisone taper: post-hoc analysis of data from the ADVOCATE trial.
Patel NJ; Jayne DRW; Merkel PA; Bekker P; Zhang Y; Yue H; Stone JH
Lancet Rheumatol; 2023 Mar; 5(3):e130-e138. PubMed ID: 38251609
[TBL] [Abstract][Full Text] [Related]
20. Being an ADVOCATE for People with ANCA Vasculitis.
Anders HJ; Nakazawa D
Clin J Am Soc Nephrol; 2021 Oct; 16(10):1581-1583. PubMed ID: 34083218
[No Abstract] [Full Text] [Related]
[Next] [New Search]
